Hunan Jiudian Pharmaceutical Co Ltd
SZSE:300705
Hunan Jiudian Pharmaceutical Co Ltd
SZSE:300705
Price:
16.82
CNY
0.3%
Market Closed
Market Cap:
8.3B
CNY
Balance Sheet
Balance Sheet Decomposition
Hunan Jiudian Pharmaceutical Co Ltd
Hunan Jiudian Pharmaceutical Co Ltd
| Current Assets | 1.6B |
| Cash & Short-Term Investments | 710m |
| Receivables | 526.3m |
| Other Current Assets | 361.2m |
| Non-Current Assets | 1.6B |
| Long-Term Investments | 92m |
| PP&E | 1.2B |
| Intangibles | 136.9m |
| Other Non-Current Assets | 168.8m |
Balance Sheet
Hunan Jiudian Pharmaceutical Co Ltd
Hunan Jiudian Pharmaceutical Co Ltd
Currency: CNY
Millions
Annual
| Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
28
|
34
|
71
|
296
|
169
|
125
|
132
|
376
|
335
|
415
|
|
| Cash |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
376
|
335
|
415
|
|
| Cash Equivalents |
28
|
34
|
71
|
296
|
169
|
125
|
132
|
0
|
0
|
0
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
100
|
90
|
90
|
|
| Total Receivables |
52
|
75
|
78
|
121
|
179
|
183
|
209
|
301
|
510
|
636
|
|
| Accounts Receivables |
32
|
45
|
52
|
82
|
112
|
131
|
164
|
249
|
458
|
546
|
|
| Other Receivables |
20
|
30
|
26
|
39
|
67
|
53
|
45
|
52
|
51
|
91
|
|
| Inventory |
56
|
64
|
78
|
96
|
109
|
136
|
153
|
214
|
241
|
266
|
|
| Other Current Assets |
11
|
8
|
8
|
6
|
10
|
9
|
10
|
29
|
31
|
23
|
|
| Total Current Assets |
146
|
181
|
235
|
519
|
466
|
454
|
504
|
1 020
|
1 206
|
1 430
|
|
| PP&E Net |
97
|
112
|
144
|
184
|
417
|
546
|
551
|
612
|
911
|
1 216
|
|
| PP&E Gross |
0
|
0
|
144
|
184
|
417
|
546
|
551
|
612
|
911
|
1 216
|
|
| Accumulated Depreciation |
0
|
0
|
46
|
58
|
75
|
104
|
143
|
186
|
235
|
297
|
|
| Intangible Assets |
22
|
20
|
17
|
52
|
53
|
52
|
51
|
77
|
100
|
112
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
4
|
3
|
34
|
34
|
|
| Other Long-Term Assets |
4
|
5
|
1
|
15
|
7
|
20
|
21
|
33
|
48
|
79
|
|
| Total Assets |
269
N/A
|
318
+19%
|
397
+25%
|
769
+94%
|
943
+23%
|
1 072
+14%
|
1 131
+5%
|
1 745
+54%
|
2 300
+32%
|
2 871
+25%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
20
|
24
|
30
|
33
|
55
|
65
|
51
|
86
|
106
|
136
|
|
| Accrued Liabilities |
3
|
1
|
5
|
10
|
18
|
25
|
36
|
50
|
63
|
75
|
|
| Short-Term Debt |
15
|
20
|
22
|
6
|
50
|
69
|
20
|
83
|
125
|
93
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
6
|
8
|
51
|
13
|
6
|
|
| Other Current Liabilities |
19
|
17
|
16
|
31
|
35
|
35
|
67
|
100
|
137
|
107
|
|
| Total Current Liabilities |
57
|
62
|
72
|
80
|
157
|
201
|
181
|
370
|
444
|
416
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
30
|
69
|
71
|
224
|
232
|
333
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
6
|
4
|
|
| Other Liabilities |
2
|
2
|
1
|
29
|
38
|
41
|
44
|
51
|
66
|
145
|
|
| Total Liabilities |
59
N/A
|
64
+9%
|
74
+15%
|
109
+48%
|
225
+107%
|
310
+38%
|
295
-5%
|
646
+119%
|
747
+16%
|
898
+20%
|
|
| Equity | |||||||||||
| Common Stock |
47
|
81
|
88
|
117
|
235
|
235
|
235
|
235
|
343
|
345
|
|
| Retained Earnings |
124
|
36
|
78
|
147
|
205
|
248
|
322
|
516
|
725
|
1 013
|
|
| Additional Paid In Capital |
39
|
138
|
157
|
396
|
279
|
279
|
279
|
279
|
485
|
530
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
69
|
0
|
85
|
|
| Total Equity |
210
N/A
|
255
+21%
|
323
+27%
|
660
+104%
|
718
+9%
|
762
+6%
|
836
+10%
|
1 099
+32%
|
1 553
+41%
|
1 973
+27%
|
|
| Total Liabilities & Equity |
269
N/A
|
318
+19%
|
397
+25%
|
769
+94%
|
943
+23%
|
1 072
+14%
|
1 131
+5%
|
1 745
+54%
|
2 300
+32%
|
2 871
+25%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
95
|
161
|
176
|
235
|
235
|
235
|
235
|
460
|
480
|
483
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
